MedPageToday -- CHICAGO -- Mildly symptomatic heart failure patients have better outcomes with the selective aldosterone-receptor blocker eplerenone (Inspra), a randomized controlled trial showed.
MedPageToday -- CHICAGO -- Mildly symptomatic heart failure patients have better outcomes with the selective aldosterone-receptor blocker eplerenone (Inspra), a randomized controlled trial showed.